MaaT Pharma (DUS:4RD) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new ordinary shares Closed: €9.1M raised · €3.48 a share · Portzamparc, BNP Paribas Group Dealers: Portzamparc, BNP Paribas Group (lead) Buyers: PSIM represented by Bpifrance Investissement (pledged to subscribe for €1.5 million); Biocodex (€1.5 million); Fonds PSIM (Bpifrance Investissement) (€1.5 million); Invus Public Entities (€1.5 million) Insiders: Existing shareholders PSIM (Bpifrance Investissement) and Biocodex pledged to subscribe €1.5 million each, €3 million in total; Biocodex's president is a board member Use of proceeds: Fund its roadmap: preparing Xervyteg commercialization, MaaT033 development, FDA discussions, working capital and general corporate purposes | Nov 14, 2025 | US$10.58M |
| Loan with warrants attached Tranche closed: €3.5M raised · Warrants at €4.5898 for 240 months · Van Lanschot Kempen Dealers: Van Lanschot Kempen Buyers: European Investment Bank (EIB) (€37.5 million, 4-tranche loan with warrants attached); European Investment Bank (Tranche A loan of €3.5 million and 468,772 warrants) Use of proceeds: Advance late-stage hemato-oncology programs, including Xervyteg and MaaT033 | Nov 4, 2025 | US$4.02M |